TriangleFG-3246 (NCT06842498)
FG-3246 trial for Metastatic Castration-Resistant Prostate Cancer (NCT06842498). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic castration-resistant prostate adenocarcinoma progressing after one androgen-receptor signaling inhibitor. Prior chemotherapy is restricted to selected earlier taxane treatment in hormone-sensitive disease.
The idea: FG-3246 carries a toxic payload to CD46-expressing cancer cells. Patients are randomized to intravenous doses of 1.8, 2.4, or 2.7 milligrams per kilogram every three weeks. Researchers compare disease control, safety, and drug levels. Suitable tumor tissue is requested when accessible; archived tissue may be used.
This phase 2 study plans 75 patients. Kyntra Bio sponsors it; 23 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.